Who is still getting HIV in America? Medication is only half the fight – homing in on disparities can help get care to those who need it most

Two-thirds of new HIV infections are among gay and bisexual men. Although cases have decreased among white men, they have stagnated among communities of color.

Angel Algarin, Assistant Professor of Health Promotion and Disease Prevention, Arizona State University • conversation
Dec. 1, 2023 ~6 min

HIV self-test kits are meant to empower those at risk − but they don't necessarily lead to starting HIV treatment or prevention

Many people at heightened risk for HIV have never been tested. Those who have self-tested for HIV often don’t go on to receive care or change their sexual behavior.

Oluwaseun Abdulganiyu Badru, Ph.D. Candidate in Community and Behavioral Health, University of Iowa • conversation
Oct. 2, 2023 ~5 min


Anemia afflicts nearly 1 in 4 people worldwide, but there are practical strategies for reducing it

Among young children, adolescents and adult women, anemia strikes 1 in 3 globally. Most cases are driven by dietary iron deficiency, red blood cell disorders and untreated tropical diseases.

Theresa A McHugh, Researcher and Scientific Writer at the Institute for Health Metrics and Evaluation, University of Washington • conversation
Sept. 8, 2023 ~8 min

Massachusetts is updating its sex education guidelines for the first time in 24 years

Twelve states do not require sex education of any kind.

Emily Rothman, Professor and Chair, Occupational Therapy; and Professor of Community Health Sciences, Boston University • conversation
July 24, 2023 ~8 min

Grassroots AIDS activists fought for and won affordable HIV treatments around the world – but PEPFAR didn't change governments and pharma

The US PEPFAR initiative has brought HIV medication to millions of people globally. Behind this progress are the activists that pressured politicians and companies to put patients over patents.

Dan Royles, Associate Professor of History, Florida International University • conversation
Jan. 24, 2023 ~10 min

Mpox, AIDS and COVID-19 show the challenges of targeting public health messaging to specific groups without causing stigma

Prejudice and stigma can discourage the communities most affected by infectious diseases from seeking care. Inclusive public health messaging can prevent misinformation and guide the most vulnerable.

Ken Ho, Assistant Professor of Infectious Diseases, University of Pittsburgh Health Sciences • conversation
Dec. 14, 2022 ~9 min

HIV therapies currently need to be taken regularly for life – longer-lasting antibody treatments could one day offer an equally effective one-shot alternative

Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.

Ronald C. Desrosiers, Professor of Pathology, Vice-chair for Research, University of Miami • conversation
Sept. 23, 2022 ~7 min

How mRNA and DNA vaccines could soon treat cancers, HIV, autoimmune disorders and genetic diseases

DNA and mRNA vaccines produce a different kind of immune response than traditional vaccines, allowing researchers to tackle some previously unsolvable problems in medicine.

Deborah Fuller, Professor of Microbiology, School of Medicine, University of Washington • conversation
Jan. 24, 2022 ~9 min


Why addressing racism against Black women in health care is key to ending the US HIV epidemic

Black American women have disproportionate HIV infection rates – in part because of systemic and structural racism in the health care system.

Nabila El-Bassel, Professor of Social Work, Director of Social Intervention Group, Columbia University • conversation
Dec. 6, 2021 ~11 min

Why COVID-19 must be included in safer sex messaging on college campuses

Schools have not adequately educated students about the increased risks of virus transmission when it comes to being sexually intimate.

Michele R. Cooley-Strickland, Project Scientist and Clinical Psychologist, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine • conversation
Dec. 2, 2021 ~9 min

/

2